Medical News

(Dana-Farber Cancer Institute) Although people with multiple myeloma usually respond well to treatment, the blood cancer generally keeps coming back. Following genetic changes in how the disease evolves over time will he...

A CRISPR system that lacks scissors to cut DNA strands can change the gene's behavior without making direct modifications on the DNA. How does this modified gene editing tool work?

"The enjoyment of the highest attainable standard of health is one of the fundamental rights of every human being without distinction of race, religion, political belief, economic or social condition". Almost 70 years af...

(Dana-Farber Cancer Institute) Daily low doses of the immune signaling protein interleukin-2 (IL-2) can safely benefit patients who develop chronic graft-versus-host disease following stem cell transplants, including par...

(University of Texas M. D. Anderson Cancer Center) A study involving the recently approved CD19-targeting chimeric antigen receptor (CAR) T cell therapy shows that 42 percent of patients with aggressive large B-cell lymp...

(Dana-Farber Cancer Institute) Researchers at Dana-Farber Cancer Institute have carried out the largest genomic analysis of patients with smoldering multiple myeloma (SMM), a precursor to full-blown blood cancer that doe...

(Dana-Farber Cancer Institute) Among younger patients newly diagnosed with chronic lymphocytic leukemia (CLL), treatment with a combination of chemotherapy and a molecularly targeted drug significantly improves response ...

(American Society of Hematology) Four studies being presented today at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta highlight the multiple ways in which novel targeted cancer the...

(Dana-Farber Cancer Institute) Clinical Activity in a Phase 1 Study of BLU-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis. Study shows one of multiple ways in which novel targete...

(University of Pennsylvania School of Medicine) In a pair of clinical trials stretching from Philadelphia to Tokyo, the chimeric antigen receptor (CAR) T cell therapy Kymriah™ (formerly known as CTL019) demonstrated lo...

This week we are highlighting projects that help advance research on penguins, seals, the Antarctica and more. Cheers! The SciStarter Team FjordPhyto Maria Stenzel This one involves a little travel to an unexpected biodi...